Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GENinCode UK Ltd. ( (GB:GENI) ) has issued an announcement.
GENinCode Plc has completed its WRAP Retail Offer, launched on 21 January 2026, raising approximately £0.2 million through the issue of 20,014,095 new ordinary shares at 1 pence per share. Subject to shareholder approval of the relevant resolutions at a forthcoming general meeting, this brings the company’s total gross proceeds from its broader fundraising to about £4.1 million, strengthening its balance sheet and providing additional capital to support its predictive genetics programmes and ongoing operations.
The most recent analyst rating on (GB:GENI) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.
Spark’s Take on GB:GENI Stock
According to Spark, TipRanks’ AI Analyst, GB:GENI is a Underperform.
Overall score is pressured primarily by weak financial performance (persistent losses, negative cash generation, and declining equity) and bearish technicals (price below major moving averages with negative MACD). Oversold momentum signals modestly temper the technical risk, but valuation remains constrained by negative earnings and lack of dividend support.
To see Spark’s full report on GB:GENI stock, click here.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based predictive genetics company specialising in tests aimed at the prevention of cardiovascular disease and ovarian cancer. Listed on AIM under the ticker GENI, it focuses on deploying genomic risk assessment technologies to improve early diagnosis and risk stratification in these major disease areas.
Average Trading Volume: 1,443,728
Technical Sentiment Signal: Sell
Current Market Cap: £3.16M
See more insights into GENI stock on TipRanks’ Stock Analysis page.